Liraglutide Reduces Food Cravings, Changes Taste Preferences, and Preferentially Burns Fat
Liraglutide 3 mg daily reduced cravings for sweet, salty, savory, and fatty foods, decreased body fat while preserving lean mass, and increased gut satiety hormones.
Quick Facts
What This Study Found
Compared to placebo, liraglutide 3 mg daily significantly reduced how much food participants wanted to eat, their desire for sweet, salty, savory, and fatty foods, and the maximum volume of a nutrient drink they could tolerate. Participants also reported feeling fuller after meals.
Liraglutide increased postprandial PYY levels (a satiety hormone) while decreasing active GLP-1 levels relative to baseline. This suggests the drug changes the gut hormone environment beyond just mimicking GLP-1.
Body composition scans showed significant reductions in total body fat, trunk fat, and both upper and lower body fat. Lean body mass was preserved, meaning the weight lost was predominantly fat.
Key Numbers
35 completers; 17 liraglutide, 18 placebo; 16 weeks; reduced total/trunk/limb fat; preserved lean mass; increased PYY, decreased active GLP-1
How They Did This
This was a substudy of a double-blind, placebo-controlled, randomized 16-week trial. Forty obese adults received weight management counseling, monthly behavioral therapy, and either liraglutide (escalated to 3 mg daily) or placebo. Appetite and taste preferences were rated every 30 minutes for 5 hours after a nutrient drink. Body composition was measured by DEXA scan.
Why This Research Matters
One of the biggest concerns with weight loss drugs is losing muscle along with fat. This study showed liraglutide preferentially reduced fat while preserving lean mass, which is important for long-term metabolic health.
The changes in taste preference are also notable. Reducing the desire for sweet and fatty foods could help people maintain weight loss after treatment ends.
The Bigger Picture
One of the biggest concerns with weight loss drugs is losing muscle along with fat. This study showed liraglutide specifically targets fat while preserving lean mass, which is critical for long-term metabolic health and physical function.
What This Study Doesn't Tell Us
This was a small study with only 35 completers. The 16-week duration cannot show whether the taste preference changes persist long-term or after stopping the drug.
All participants received behavioral therapy, so the liraglutide effects cannot be fully separated from the counseling effects.
Questions This Raises
- ?Do taste preference changes persist after stopping liraglutide?
- ?Is the lean mass preservation maintained with longer treatment?
- ?Does regional fat loss (trunk vs limbs) differ between GLP-1 drugs?
Trust & Context
- Key Stat:
- Fat ↓ Lean preserved liraglutide specifically reduced body fat while maintaining lean muscle mass, addressing a key concern in weight loss therapy
- Evidence Grade:
- Moderate evidence from a small (n=35) but well-designed double-blind, placebo-controlled RCT.
- Study Age:
- Published in 2020. Body composition effects of GLP-1 drugs have been further confirmed in larger studies since.
- Original Title:
- GLP-1 Analog Modulates Appetite, Taste Preference, Gut Hormones, and Regional Body Fat Stores in Adults with Obesity.
- Published In:
- The Journal of clinical endocrinology and metabolism, 105(5), 1552-63 (2020)
- Authors:
- Kadouh, Hoda, Chedid, Victor, Halawi, Houssam(2), Burton, Duane D, Clark, Matthew M, Khemani, Disha, Vella, Adrian, Acosta, Andres, Camilleri, Michael
- Database ID:
- RPEP-04891
Evidence Hierarchy
Frequently Asked Questions
Will GLP-1 drugs change what foods I want to eat?
This study found liraglutide reduced desire for sweet, salty, savory, and fatty foods equally. Many patients on GLP-1 drugs report naturally losing interest in high-calorie foods.
Will I lose muscle along with fat?
This study showed liraglutide preferentially reduced fat while preserving lean mass. Combining GLP-1 therapy with protein intake and exercise is recommended to maintain muscle during weight loss.
Read More on RethinkPeptides
Cite This Study
https://rethinkpeptides.com/research/RPEP-04891APA
Kadouh, Hoda; Chedid, Victor; Halawi, Houssam; Burton, Duane D; Clark, Matthew M; Khemani, Disha; Vella, Adrian; Acosta, Andres; Camilleri, Michael. (2020). GLP-1 Analog Modulates Appetite, Taste Preference, Gut Hormones, and Regional Body Fat Stores in Adults with Obesity.. The Journal of clinical endocrinology and metabolism, 105(5), 1552-63. https://doi.org/10.1210/clinem/dgz140
MLA
Kadouh, Hoda, et al. "GLP-1 Analog Modulates Appetite, Taste Preference, Gut Hormones, and Regional Body Fat Stores in Adults with Obesity.." The Journal of clinical endocrinology and metabolism, 2020. https://doi.org/10.1210/clinem/dgz140
RethinkPeptides
RethinkPeptides Research Database. "GLP-1 Analog Modulates Appetite, Taste Preference, Gut Hormo..." RPEP-04891. Retrieved from https://rethinkpeptides.com/research/kadouh-2020-glp1-analog-modulates-appetite
Access the Original Study
Study data sourced from PubMed, a service of the U.S. National Library of Medicine, National Institutes of Health.
This study breakdown was produced by the RethinkPeptides research team. We analyze and report published research findings without making health recommendations. All interpretations are based solely on the published abstract and study data.